Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from COR

What to Expect From Cencora's Next Quarterly Earnings Report

Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.

Barchart

How Is Cencora’s Stock Performance Compared to Other Medical Stocks?

While Cencora’s recent performance has lagged behind other healthcare stocks, analysts express strong confidence in its long-term growth potential.

Barchart

Melbourne-based startup Cor raises US $2 million to bring AI video onboarding to enterprise software

Melbourne-founded startup Cor announced that it has secured US $2 million in a pre-seed funding round to support development of its flagship product, Obi — a generative-video-AI agent designed to guide users through new software via an interactive, personalised onboarding experience.

inkl

From analysis to the latest developments in health,
read the most diverse news in one place.

Cencora Stock: Is Wall Street Bullish or Bearish?

Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.

Benzinga

What to Expect From Cencora's Q4 2025 Earnings Report

Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.

Barchart

EXCLUSIVE: Worksport Reports Record Q3 Revenue, Gross Profit

Worksport (NASDAQ:WKSP) on Thursday announced its unaudited top-line results for the third quarter of 2025, reporting record quarterly revenue and gross profit.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Cencora Stock: Is COR Outperforming the Health Care Sector?

Cencora has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Bitcoin, XRP Treasury Strategy Paying Off? Worksport Reports Record Sales

Worksport Ltd. (NASDAQ:WKSP), which earlier this year adopted Bitcoin (CRYPTO: BTC) and Ripple (CRYPTO: XRP) as part of its corporate treasury, reported on Tuesday that it reached a 31% gross margin in July, one quarter ahead of its year-end target.

Benzinga

Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

Barchart

Wall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday?

U.S. stocks rebounded sharply on Wednesday, fully erasing last Friday's losses, as upbeat corporate earnings and renewed investor optimism outweighed concerns over escalating trade tensions.

Benzinga

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Benzinga

Here's What to Expect From Cencora's Next Earnings Report

Cencora is scheduled to release its second-quarter results next month, with analysts projecting double-digit earnings growth.

Barchart

Is Cencora Stock Outperforming the Dow?

Due to Cencora’s strong performance relative to the broader Dow over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Do Wall Street Analysts Like Cencora Stock?

Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Barchart

Earnings Preview: What To Expect From Cencora's Report

Cencora is scheduled to report its second-quarter results next month, with analysts projecting a single-digit earnings growth.

Barchart

This ‘Recession-Proof’ Stock Just Set New Highs and Is Flashing ‘Buy’ Signals

Drug stocks like Cencora tend to be recession-proof, making today’s Chart of the Day especially relevant following a tariffs-driven selloff.

Barchart

Is Cencora Stock Outperforming the Nasdaq?

As Cencora has outperformed relative to the broader Nasdaq Composite over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Cencora Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.

Barchart

Cencora's Quarterly Earnings Preview: What You Need to Know

As Cencora prepares to release its first-quarter earnings this month, analysts project a modest single-digit bottom-line surge.

Barchart

Is Cencora Stock Underperforming the S&P 500?

Cencora has trailed the S&P 500 index over the past year, but analysts remain highly bullish about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Cencora Stock Will Climb or Sink?

Cencora has underperformed the broader market over the past year, and Wall Street analysts appear moderately bullish about the stock’s future.

Barchart

Cencora's Q4 2024 Earnings: What to Expect

Cencora is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Barchart

How Is Cencora's Stock Performance Compared to Other Healthcare Stocks?

Cencora has outperformed other healthcare stocks over the past year and analysts remain bullish about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Cencora Stock?

Cencora has outperformed the broader market over the past year, and Wall Street analysts remain bullish about the stock's prospects.

1 2

Organisations

Advanced Micro Devices, Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.